ECSP066392A - - Google Patents
Info
- Publication number
- ECSP066392A ECSP066392A EC2006006392A ECSP066392A ECSP066392A EC SP066392 A ECSP066392 A EC SP066392A EC 2006006392 A EC2006006392 A EC 2006006392A EC SP066392 A ECSP066392 A EC SP066392A EC SP066392 A ECSP066392 A EC SP066392A
- Authority
- EC
- Ecuador
- Prior art keywords
- receptors
- activity
- modulate
- symptoms
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporcionan compuestos, composiciones y métodos para modular la actividad de receptores y para el tratamiento, prevención, o mejora de uno o más síntomas de una enfermedad o trastorno relacionado con la actividad de los receptores.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48985403P | 2003-07-23 | 2003-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066392A true ECSP066392A (es) | 2007-01-26 |
Family
ID=34102943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006392A ECSP066392A (es) | 2003-07-23 | 2006-02-23 |
Country Status (14)
Country | Link |
---|---|
US (1) | US8466143B2 (es) |
EP (1) | EP1648408A4 (es) |
JP (1) | JP4679517B2 (es) |
KR (1) | KR20060052867A (es) |
CN (1) | CN1852748A (es) |
AU (1) | AU2004259009A1 (es) |
BR (1) | BRPI0412262A (es) |
CA (1) | CA2532798C (es) |
CR (1) | CR8258A (es) |
EC (1) | ECSP066392A (es) |
IL (1) | IL173287A0 (es) |
NO (1) | NO20060871L (es) |
RU (1) | RU2006105646A (es) |
WO (1) | WO2005009387A2 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
ATE420881T1 (de) | 2003-09-17 | 2009-01-15 | Janssen Pharmaceutica Nv | Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors |
JP2008533117A (ja) | 2005-03-14 | 2008-08-21 | グラクソ グループ リミテッド | ヒスタミンh3受容体に対して親和性を有する縮合チアゾール誘導体 |
AU2006325815B2 (en) * | 2005-12-15 | 2012-07-05 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
US20080299118A1 (en) * | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for the Treatment of Malignancies |
US20080300235A1 (en) * | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for Reducing LOX-1 Expression |
US20090163474A1 (en) * | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
US20090215748A1 (en) * | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
CA2742320A1 (en) | 2008-10-31 | 2010-05-06 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles containing rigid moieties |
JP5551708B2 (ja) * | 2008-10-31 | 2014-07-16 | メディベイション テクノロジーズ, インコーポレイテッド | アゼピノ[4,5−b]インドール化合物およびその使用方法 |
CN101875627B (zh) * | 2009-04-30 | 2014-01-15 | 凯惠科技发展(上海)有限公司 | 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体 |
ES2423668T3 (es) | 2009-05-22 | 2013-09-23 | Abbvie Inc. | Moduladores de receptores 5-HT y métodos de uso de los mismos |
WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
US9193728B2 (en) | 2010-02-18 | 2015-11-24 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
AU2010353724B2 (en) | 2010-05-21 | 2015-02-12 | AbbVie Deutschland GmbH & Co. KG | Modulators of 5-HT receptors and methods of use thereof |
CA2827642A1 (en) | 2011-02-18 | 2012-11-15 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
WO2014031165A1 (en) * | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
MX370480B (es) * | 2014-11-21 | 2019-12-16 | Akarna Therapeutics Ltd | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. |
CA2971755A1 (en) * | 2014-12-22 | 2016-06-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
TWI698430B (zh) * | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
JP6843061B2 (ja) * | 2015-03-26 | 2021-03-17 | アカーナ・セラピューティクス・リミテッドAkarna Therapeutics, Ltd. | 疾患治療のための縮合二環化合物 |
WO2017143134A1 (en) * | 2016-02-19 | 2017-08-24 | Alios Biopharma, Inc. | Fxr modulators and methods of their use |
MX2018014024A (es) * | 2016-05-25 | 2019-08-29 | Akarna Therapeutics Ltd | Terapias de combinación con moduladores del receptor x farnesoide (fxr). |
US20200325140A1 (en) * | 2016-05-25 | 2020-10-15 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
CA3065313A1 (en) * | 2017-06-02 | 2018-12-06 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds |
MA51672A (fr) | 2018-01-26 | 2020-12-02 | Exelixis Inc | Composés destinés au traitement des troubles kinases-dépendants |
US11673897B2 (en) | 2018-01-26 | 2023-06-13 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR35044B (el) * | 1966-05-10 | 1968-07-31 | The Upjohn Company | Μεθοδος παρασκευης οργανικων ενωσεων. |
US4362739A (en) * | 1981-05-04 | 1982-12-07 | S.A. Omnichem | Pyrrolo(2,3-d)carbazole derivatives, compositions and use |
IL101851A (en) * | 1991-06-13 | 1996-05-14 | Janssen Pharmaceutica Nv | History 01 -) 4 - Pipridinyl - and Pipridinylidene (- Imidazo] A-1,2 [Pirolo, Thiano or Purano (] 3,2 [Azpin, their preparation and pharmaceutical preparations containing them and composition |
JPH09221475A (ja) * | 1996-02-13 | 1997-08-26 | Yamanouchi Pharmaceut Co Ltd | 新規なオキシム誘導体 |
AU8766498A (en) * | 1997-08-04 | 1999-02-22 | Amgen, Inc. | Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors |
JP2003508031A (ja) | 1999-06-18 | 2003-03-04 | スィーヴィー セラピューティクス インコーポレイテッド | Atp結合カセット輸送体蛋白質abc1を用いるコレステロール流出を増加させhdlを上昇させるための組成物および方法 |
FR2796070B1 (fr) * | 1999-07-06 | 2003-02-21 | Lipha | Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation |
MY122278A (en) | 1999-07-19 | 2006-04-29 | Upjohn Co | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position |
US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
AU2006325815B2 (en) * | 2005-12-15 | 2012-07-05 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
-
2004
- 2004-07-23 AU AU2004259009A patent/AU2004259009A1/en not_active Abandoned
- 2004-07-23 CA CA2532798A patent/CA2532798C/en not_active Expired - Fee Related
- 2004-07-23 US US10/565,702 patent/US8466143B2/en active Active
- 2004-07-23 KR KR1020067001566A patent/KR20060052867A/ko not_active Application Discontinuation
- 2004-07-23 RU RU2006105646/04A patent/RU2006105646A/ru not_active Application Discontinuation
- 2004-07-23 CN CNA2004800270768A patent/CN1852748A/zh active Pending
- 2004-07-23 EP EP04779004A patent/EP1648408A4/en not_active Withdrawn
- 2004-07-23 BR BRPI0412262-3A patent/BRPI0412262A/pt not_active IP Right Cessation
- 2004-07-23 JP JP2006521272A patent/JP4679517B2/ja not_active Expired - Fee Related
- 2004-07-23 WO PCT/US2004/023745 patent/WO2005009387A2/en active Application Filing
-
2006
- 2006-01-22 IL IL173287A patent/IL173287A0/en unknown
- 2006-02-22 NO NO20060871A patent/NO20060871L/no not_active Application Discontinuation
- 2006-02-23 EC EC2006006392A patent/ECSP066392A/es unknown
- 2006-02-23 CR CR8258A patent/CR8258A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2006528637A (ja) | 2006-12-21 |
CA2532798A1 (en) | 2005-02-03 |
EP1648408A4 (en) | 2006-11-29 |
WO2005009387A2 (en) | 2005-02-03 |
NO20060871L (no) | 2006-04-24 |
US8466143B2 (en) | 2013-06-18 |
JP4679517B2 (ja) | 2011-04-27 |
CA2532798C (en) | 2013-02-19 |
AU2004259009A1 (en) | 2005-02-03 |
RU2006105646A (ru) | 2007-09-10 |
CN1852748A (zh) | 2006-10-25 |
BRPI0412262A (pt) | 2006-09-19 |
US20070015746A1 (en) | 2007-01-18 |
EP1648408A1 (en) | 2006-04-26 |
IL173287A0 (en) | 2006-06-11 |
CR8258A (es) | 2006-08-30 |
KR20060052867A (ko) | 2006-05-19 |
WO2005009387A3 (en) | 2006-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066392A (es) | ||
CR8497A (es) | Derivados de azepinoindol como agentes farmaceuticos | |
NO20081975L (no) | Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer | |
CR10277A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
NO20081788L (no) | Cyklopropylaminer som modulatorer av histamin-H3-reseptoren | |
TW200607491A (en) | Aryl sulfonamide and sulfonyl compounds as modulators of ppar and methods of treating metabolic disorders | |
GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
EA201000784A1 (ru) | Антагонисты пути hedgehog и их терапевтические применения | |
TW200745124A (en) | Azepinoindole derivatives as pharmaceutical agents | |
NI200900031A (es) | Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos. | |
UY26130A1 (es) | Compuestos para tratar la obesidad | |
BRPI0511527A (pt) | compostos e composições como moduladores de ppar | |
BRPI0417717A (pt) | composto, composição farmacêutica, e, uso de um composto | |
ES2422557T3 (es) | Compuestos y composiciones como moduladores de la ruta Hedgehog | |
BRPI0513677B8 (pt) | derivados de pirrol como agentes farmacêuticos | |
PA8570701A1 (es) | Compuestos que modulan la actividad de ppar y procedimientos para su preparacion | |
NO20054407L (no) | Cannabinoid reseptor ligander og deres anvendelser | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
GT200300053A (es) | Compuestos que modulan la actividad de ppar | |
ATE472529T1 (de) | Prolinamidderivate als natriumkanalmodulatoren | |
GT200300054A (es) | Compuestos que modulan la actividad de ppar | |
NO341679B1 (no) | Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren | |
NO20081160L (no) | Benzimidazoltiofen forbindelser | |
CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
NO20063393L (no) | Farmasoytiske preparater |